QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$16.08
-0.29 (-1.77%)
(As of 06/7/2023 ET)
Compare
Today's Range
$16.05
▼
$16.21
50-Day Range
$15.84
▼
$17.11
52-Week Range
$12.28
▼
$17.15
Volume
1.44 million shs
Average Volume
2.50 million shs
Market Capitalization
$50.90 billion
P/E Ratio
20.89
Dividend Yield
1.68%
Price Target
$24.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
53.4% Upside
$24.67 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.32mentions of Takeda Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

324th out of 981 stocks

Pharmaceutical Preparations Industry

141st out of 463 stocks

See Top Rated MarketRank™ Stocks Here

TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

June 7, 2023 | benzinga.com
Enhancing Care: Expansion of Alpers Disease Treatment Market Size On its Path to US$ 1.90 Billion by 2030, at a 4.57% of CAGR.
June 6, 2023 | americanbankingnews.com
Takeda Pharmaceutical Company Limited (NYSE:TAK) Given Consensus Recommendation of "Moderate Buy" by Brokerages
June 7, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 2, 2023 | finance.yahoo.com
The area's largest life sciences employer, Takeda keeps reinventing itself
May 26, 2023 | bizjournals.com
This drug could help children with brain cancer. What's taken it so long?
May 26, 2023 | finance.yahoo.com
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
May 25, 2023 | finance.yahoo.com
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023 | fool.com
Takeda Pharmaceutical (NYSE: TAK)
June 7, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
May 25, 2023 | benzinga.com
Government of Japan Expresses its Pledge of US$200 Million to GHIT Fund/UNDP Replenishment
May 22, 2023 | finance.yahoo.com
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
May 17, 2023 | marketwatch.com
2023 Dipeptidyl Peptidase-4 Inhibitors Market Size and Insight Report in Pharma & Healthcare Sector | with [100 Pages] and Forecast till 2031
May 17, 2023 | marketwatch.com
Axial Spondyloarthritis Market Analysis by Size, Share, Trends, Emerging Trends, Qualitative Outlook and Worldwide Forecast to 2030
May 17, 2023 | americanbankingnews.com
Takeda Pharmaceutical Company Limited (NYSE:TAK) Receives Consensus Recommendation of "Moderate Buy" from Analysts
May 17, 2023 | marketwatch.com
2023-2030 Blow-Fill-Seal (BFS) Technology Market: Highlights with Growth Rate
May 16, 2023 | benzinga.com
Global Blood Cancer Drugs Market Report 2023: Increasing Prevalence of Blood Cancer Cases Drives Growth
May 16, 2023 | finance.yahoo.com
Takeda Pharmaceutical Company Limited (NYSE:TAK) Q4 2022 Earnings Call Transcript
May 15, 2023 | benzinga.com
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
May 15, 2023 | americanbankingnews.com
Takeda Pharmaceutical (NYSE:TAK) Issues FY 2023 Earnings Guidance
May 11, 2023 | msn.com
Takeda FY22 sales grow but FY23 outlook weighed down by generic impact
May 11, 2023 | finance.yahoo.com
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
May 11, 2023 | marketwatch.com
Takeda Pharmaceutical 4Q Rev Y960.00B, Given Y3.07T Rev in Preceding 9 Mos, WSJ Calculation Shows>4502.TO
May 11, 2023 | finance.yahoo.com
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
May 10, 2023 | finance.yahoo.com
Takeda Presents Real-World Clinical Effectiveness and Safety Results of Vedolizumab (ENTYVIO®) and Ustekinumab as First-Line Biologic Treatment for Crohn's Disease
May 8, 2023 | bizjournals.com
Takeda to lay off up to 186 employees in Massachusetts
May 5, 2023 | marketwatch.com
2030 Pericarditis Drugs Market Forecast: Positive Growth Trajectory Ahead
May 4, 2023 | marketwatch.com
Lipid Metabolism Disease Market Size and Forecast till 2031
See More Headlines

TAK Price History

TAK Company Calendar

Today
6/07/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TAK
CUSIP
N/A
CIK
1395064
Web
www.takeda.com
Phone
(166) 204-2111
Fax
813-3278-2268
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+53.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.77
Trailing P/E Ratio
20.90
Forward P/E Ratio
48.76
P/E Growth
9.02
Net Income
$2.35 billion
Net Margins
7.91%
Pretax Margin
9.31%
Return on Equity
12.73%
Return on Assets
5.80%

Debt

Debt-to-Equity Ratio
0.64
Current Ratio
0.97
Quick Ratio
0.57

Sales & Book Value

Annual Sales
$29.81 billion
Price / Sales
1.71
Cash Flow
$3.60 per share
Price / Cash Flow
4.47
Book Value
$14.86 per share
Price / Book
1.08

Miscellaneous

Outstanding Shares
3,164,620,000
Free Float
3,163,350,000
Market Cap
$50.92 billion
Optionable
Optionable
Beta
0.63

Social Links


Key Executives

  • Christophe Weber
    President, CEO & Representative Director
  • Constantine Saroukos
    Chief Financial Officer & Director
  • Andrew S. Plump
    Director, President-Research & Development
  • Michael E. Mendelsohn
    Chief Medical & Scientific Officer
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TAK shares.
View TAK analyst ratings or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

5 Wall Street research analysts have issued 12-month target prices for Takeda Pharmaceutical's stock. Their TAK share price forecasts range from $20.00 to $30.00. On average, they predict the company's share price to reach $24.67 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price.
View analysts price targets for TAK or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of 2023. Since then, TAK stock has increased by 3.1% and is now trading at $16.09.
View the best growth stocks for 2023 here.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our TAK earnings forecast.

What ETFs hold Takeda Pharmaceutical's stock?

ETFs with the largest weight of Takeda Pharmaceutical (NYSE:TAK) stock in their portfolio include VanEck Pharmaceutical ETF (PPH), First Trust International IPO ETF (FPXI), Pacer Developed Markets International Cash Cows 100 ETF (ICOW), B.A.D. Etf (BAD), Pacer Global Cash Cows Dividend ETF (GCOW), ETFMG Treatments Testing and Advancements ETF (GERM), Invesco Zacks Multi-Asset Income ETF (CVY) and Pacer Trendpilot International ETF (PTIN).

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.68%. The dividend payout ratio is 35.07%. This payout ratio is at a healthy, sustainable level, below 75%.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of $3.28-$3.28 for the period. The company issued revenue guidance of $29.03 billion-$29.03 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.15%), Mondrian Investment Partners LTD (0.13%), Macquarie Group Ltd. (0.12%), Macquarie Group Ltd. (0.12%), Renaissance Technologies LLC (0.09%) and BlackRock Inc. (0.08%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $16.09.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $50.92 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.77 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -